TESARO, Inc. (NASDAQ:TSRO) – Equities research analysts at SunTrust Banks dropped their Q3 2017 earnings estimates for TESARO in a research report issued on Tuesday. SunTrust Banks analyst P. Lawson now forecasts that the biopharmaceutical company will post earnings of ($2.57) per share for the quarter, down from their prior estimate of ($1.51). SunTrust Banks also issued estimates for TESARO’s Q4 2017 earnings at ($2.47) EPS, FY2017 earnings at ($10.40) EPS, FY2018 earnings at ($5.26) EPS and FY2019 earnings at ($1.50) EPS.
TSRO has been the topic of a number of other research reports. BidaskClub lowered TESARO from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Robert W. Baird restated a “neutral” rating on shares of TESARO in a research report on Tuesday, June 6th. Bank of America Corporation restated a “buy” rating and set a $154.00 price objective on shares of TESARO in a research report on Tuesday, June 20th. Wedbush upgraded TESARO to an “outperform” rating and set a $168.00 price objective on the stock in a research report on Monday, June 5th. Finally, ValuEngine lowered TESARO from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $176.35.
TESARO (NASDAQ TSRO) opened at 110.89 on Friday. The company’s market cap is $5.99 billion. TESARO has a 12-month low of $83.26 and a 12-month high of $192.94. The company has a 50-day moving average price of $131.54 and a 200 day moving average price of $149.39.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.52) by $0.30. The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative net margin of 1,301.19% and a negative return on equity of 104.00%. TESARO’s revenue was down 17.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.28) EPS.
In other TESARO news, VP Edward C. English sold 8,500 shares of the company’s stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total value of $1,178,525.00. Following the sale, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 40.50% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Trellus Management Company LLC acquired a new stake in shares of TESARO during the first quarter valued at approximately $1,154,000. Tocqueville Asset Management L.P. raised its stake in shares of TESARO by 11.1% in the first quarter. Tocqueville Asset Management L.P. now owns 62,055 shares of the biopharmaceutical company’s stock valued at $9,548,000 after buying an additional 6,225 shares during the last quarter. Whittier Trust Co. raised its stake in shares of TESARO by 4.8% in the first quarter. Whittier Trust Co. now owns 11,186 shares of the biopharmaceutical company’s stock valued at $1,721,000 after buying an additional 515 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of TESARO by 3.9% in the first quarter. Russell Investments Group Ltd. now owns 25,329 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 954 shares during the last quarter. Finally, Strs Ohio raised its stake in shares of TESARO by 11.6% in the first quarter. Strs Ohio now owns 4,800 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 500 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.